Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
14 Cards in this Set
- Front
- Back
|
Pentamidine
Pharmacologic Category |
Antibiotic
|
|
|
Pentamidine
Use |
Tx and prevention of pneumonia caused by Pneumocystis jiroveca (PCP)
|
|
|
Pentamidine
Route of Administration & Dose |
IM or IV
PCP treatment 4 mg/kg/day once daily for 10-14 days |
|
|
Pentamidine
Prophylaxis |
IM or IV 4mg/kg monthly or every 2 weeks
Inhalation or aerosolized pentamidine in children > 5 years : 300 mg/dose every 3-4 weeks via Respirgard II inhaler in children ,5: 8mg/kg dose |
|
|
Pentamidine
Adverse Reaction |
hypotension, superinfection (C.Diff and pseudomembranous colitis)
Fatigue and dizziness Rash Hyperkalemia anorexia increased Cr |
|
|
Pentamidine
Administration Implications |
pt should be lying down
Blood pressure, cardiac and respiratory should be monitored Check LFTS, renal, blood glucose, serum potassium and CA, ECG, adn CBC with platelets |
|
|
Pentamidine
Mechanism of Action |
Interferes with RNA/DNA, phospholipds and protien synthesis through inhibition of oxidative phosphorylation and/or interference with incorporation of nucleotides and nucleic acids into RNA and DNA in protozoa
- known to prolong the QT interval |
|
|
Pentamidine
Excrete |
Urine
|
|
|
Pentamidine
Half Life ellimination |
6.9 - 9.4 hours, may increase with renal impairment
|
|
|
Danazol Class
|
Androgen
|
|
|
Danazol Function
|
Suppresses pituitary output of follicle-stimulating hormone and luteinizing hormone that causes regression and atrophy of normal and ectopic endometrial tissue; decreases rate of growth of abnormal breast tissue; reduces attacks associated with hereditary angioedema by increasing levels of C4 component of complement
|
|
|
Valcyte Class
Valganciclovir |
Antiviral agent
|
|
|
Valcyte MOA
Valganciclovir |
Valganciclovir is rapidly converted to ganciclovir in the body. The bioavailability of ganciclovir from valganciclovir is increased 10-fold compared to oral ganciclovir. A dose of 900 mg achieved systemic exposure of ganciclovir comparable to that achieved with the recommended doses of intravenous ganciclovir of 5 mg/kg. Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.
|
|
|
Valcyte Labs to Monitor
Valganciclovir |
Retinal exam (at least every 4-6 weeks), CBC, platelet counts, serum creatinine
|
